2022 Jun;39(6):1233-1248
A 30-second strength test you can do today Philip Pape 30:06 For most adults who are in this midlife range, you know, 40s, 50s, 60s, somewhere in the low teens is average strength
Skin rejuvenation and anti-aging GHK-Cu is one of the most extensively studied peptides in aesthetic and dermatological medicine
Balancing sensitivity, selectivity, and robustness across the full peptide lifecycle remains a key challenge
Always follow the specific expiration date provided by your pharmacy
Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
